EUVIMEDEUVIMED entdecken
Systematische Übersicht

Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review

John A Damianos iD, Olufemi Osikoya, Gregory Brennan

Inflammatory Bowel Diseases · 10.04.2025 · 31 (4) · 1145-1149

DOI: 10.1093/ibd/izae191 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.08.2024. Verfasst von John A Damianos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute severe ulcerative colitis (ASUC) remains a clinical challenge associated with considerable morbidity, including colectomy. Upadacitinib (UPA), a selective Janus kinase (JAK)-1 inhibitor, is approved for moderate-to-severe ulcerative colitis in patients intolerant or not responding to tumor necrosis factor-alpha inhibitors. It has also increasingly been used off-label for ASUC. We performed a systematic review of all available literature on UPA in ASUC. We identified 11 studies, with a pooled total of 55 patients. Most patients experienced rapid and sustained improvement. Colectomy rate at 90 days was 16.3%. Among those who did not get colectomy, 80% were in steroid-free remission at follow-up. The reported adverse events were low, including 2 venous thromboembolic events. Overall, UPA appears to represent a safe and effective therapy for ASUC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsHumansColectomyAcute DiseaseSeverity of Illness Index

Stichwörter der Autor:innen

acute severe ulcerative colitisadvanced therapiessmall moleculesulcerative colitisupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Department of Internal Medicine, UNTHSC, Medical City, Arlington, TX, USA.
  • GI Alliance, Mansfield, TX, USA.

ORCID-Profile: John A Damianos

Zitieren

APA

Damianos, J. A., Osikoya, O., & Brennan, G. (2025). Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review. Inflammatory Bowel Diseases, 31(4), 1145-1149. https://doi.org/10.1093/ibd/izae191

Vancouver

Damianos JA, Osikoya O, Brennan G. Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review. Inflammatory Bowel Diseases. 2025;31(4):1145-1149. doi:10.1093/ibd/izae191

BibTeX
@article{Damianos2025,
  author = {Damianos, John A and Osikoya, Olufemi and Brennan, Gregory},
  title = {Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {1145--1149},
  doi = {10.1093/ibd/izae191}
}
Kostenlos starten →